Skip to main content

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Deracoxib

Detailed information about Deracoxib

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake
Showing simplified owner view. Switch to Vet View for full technical detail.

Pet Owner Quick Guide

Start here: what this medicine is for, what it does, and when it's usually needed.

Usually used for:

For the control of pain and inflammation associated with osteoarthritis, for the control of postoperative pain and inflammation associated with orthopedic surgery, and for the control of postoperative pain and inflammati...

What it does:

DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inf...

When it's needed:

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaki...

Call your vet sooner if you notice:

  • Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

Commonly reported reactions:

  • (1 reports)
  • (1 reports)
  • (1 reports)

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Talk to a Vet / Find a Vet Near You
Image coming soon
Deracoxib

Deracoxib

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: MSK

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: MSK
Form: Chewable Tablets
Identifiers:
ANADA: 200637 ANADA: 200704 NADA: 141203 NDC Package: 11695-6995-1 NDC Package: 11695-6995-2 NDC Package: 11695-6996-1 NDC Package: 11695-6996-2 NDC Package: 11695-6997-1 NDC Package: 11695-6997-2 NDC Package: 11695-6998-1 NDC Package: 11695-6998-2 NDC Package: 13744-530-01 NDC Package: 13744-530-02 NDC Package: 13744-531-01 NDC Package: 13744-531-02 NDC Package: 13744-532-01 NDC Package: 13744-532-02 NDC Package: 13744-533-01 NDC Package: 13744-533-02 NDC Package: 13985-958-30
Source metadata:

Warnings / Contraindications

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
31
Serious reports
26
Species represented
2
Most Reported Reactions
Reaction Cases Species Serious cases
1 Dog 1
1 Dog 1
1 Dog 1
1 Dog 1
1 Dog 1
1 Dog 1
1 Dog 1
1 Dog 1

Species coverage: Dog (27) Cat (5)

View detailed reaction table
Reaction Species Seriousness Frequency Reports
Cat Non-serious - 1
Dog Non-serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Non-serious - 1
Cat Non-serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Serious - 1
Dog Non-serious - 1
Dog Serious - 1
Dog Serious - 1
Cat Unknown - -
Source metadata:

Storage & Handling

No storage/handling guidance is linked yet.

Source metadata: No source yet.

Documents

Official label facts are separated from secondary summaries.

Official documents: 16 • Secondary summaries: 0

Official label facts
Secondary summaries

No source yet.

Source metadata:

Promotional Materials (Marketing)

This content is marketing material and not clinical guidance.

No marketing assets are linked yet.

No source yet.

Source metadata: No source yet.
Talk to a Vet / Find a Vet Near You
Technical appendix (vet reference)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Feb 16, 2026, 11:00 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:20 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Deracoxib Chewable Tablets Deramaxx® Chewable Tablets Doxidyl™
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Chewable Tablets • Oral
Applications: ANADA 200-704 • NADA 141-203 • ANADA 200-637
Documents: 13 (FOI: 7) • SPL: 3 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 52 • Cat 4 • View
Case summaries: 7 (showing 7) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: M19.90
Unspecified osteoarthritis, unspecified site

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Accidental exposure (1) Anorexia (1) Arthritis (1) Ataxia (1) Blood in vomit (1) Bloody stool (1) Death (1) Decreased haematocrit (1) Ecchymosis (1) Elevated creatinine (1) Emesis (multiple) (1) Falling (1) General illness (1) Head tilt - neurological disorder (see also Head tilt - ear disorder) (1) Horizontal nystagmus (1) Inappetence (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200637 ANADA: 200704 NADA: 141203 NDC Package: 11695-6995-1 NDC Package: 11695-6995-2 NDC Package: 11695-6996-1 NDC Package: 11695-6996-2 NDC Package: 11695-6997-1 NDC Package: 11695-6997-2 NDC Package: 11695-6998-1 NDC Package: 11695-6998-2 NDC Package: 13744-530-01 NDC Package: 13744-530-02 NDC Package: 13744-531-01 NDC Package: 13744-531-02 NDC Package: 13744-532-01 NDC Package: 13744-532-02 NDC Package: 13744-533-01 NDC Package: 13744-533-02 NDC Package: 13985-958-30 NDC Package: 13985-958-90 NDC Package: 13985-959-30 NDC Package: 13985-959-90 NDC Package: 13985-960-30
Package NDC Product NDC Form / Route Status
11695-6995-1 11695 -
11695-6995-2 11695 -
11695-6996-1 11695 -
11695-6996-2 11695 -
11695-6997-1 11695 -
11695-6997-2 11695 -
11695-6998-1 11695 -
11695-6998-2 11695 -
13744-530-01 13744 -
13744-530-02 13744 -
13744-531-01 13744 -
13744-531-02 13744 -
13744-532-01 13744 -
13744-532-02 13744 -
13744-533-01 13744 -
13744-533-02 13744 -
13985-958-30 13985 -
13985-958-90 13985 -
13985-959-30 13985 -
13985-959-90 13985 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Revision History

Every non-trivial field is expected to include provenance and update timestamps.

Official 16 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not atte… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Other abnormal test result NOS, Diarrhoea,… (Official, 2026-02-12)
  • usage: DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs. DERAMAXX Chewable Tablet… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Deracoxib Chewable Tablets
RX
Deracoxib
Chewable Tablets • Oral
Label highlights
Official documents
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-704 Approved Nov 14, 2023
Deramaxx® Chewable Tablets
RX
Deracoxib
Chewable Tablets • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-203 Approved Apr 8, 2020
Doxidyl™
RX
Deracoxib
Chewable Tablets • Oral
Label highlights
Official documents
Ceva Sante Animale ANADA 200-637 Approved Oct 29, 2019

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
12 mg, 25 mg, 75 mg, or 100 mg of deracoxib per tablet
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis, for the control of postoperative pain and inflammation associated with orthopedic surgery, and for the control of postoperative pain and inflammation associated with dental surgery.

Dosage

Osteoarthritis Pain and Inflammation: 0.45 - 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, as needed.

Postoperative Orthopedic Pain and Inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration.

Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each chewable tablet contains 12, 25, 50, 75, or 100 milligrams (mg) deracoxib.
Dogs
Indication
DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs.
Dosage
0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Indication
DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs.
Dosage
1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Indication
DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Dosage
0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/ day) as a single daily dose, as needed.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
12 mg, 25 mg, 75 mg or 100 mg deracoxib
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis in dogs, for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs, and for the control of postoperative pain and inflammation associated with dental surgery in dogs.

Dosage

Osteoarthritis Pain and Inflammation: 0.45-0.91 mg/lb/day (1 to 2 mg/kg/day) as a single dose, as needed. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Postoperative Orthopedic Pain and Inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days. The first dose should be given approximately 1 hour prior to dental surgery and subsequent doses should be given daily for up to two additional treatments. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Limitations

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    The supplemental NADA provides for the addition of a new indication for the control of postoperative pain and inflammation associated with dental surgery in dogs at a dose of 0.45-0.91 mg/lb (1-2 mg/kg) administered orally once daily for 3 days.
  • Summary
    This supplement provides for the addition of a 50-mg tablet size.
  • Summary
    This supplement provides for the addition of a 75 mg tablet size.
  • Summary
    The supplement to NADA 141-203 provides revisions to 21 CFR 520.538. Indications for Use. To add a claim for the control of pain and inflammation associated with osteoarthritis in dogs. Amount: To add a new dose range of 1-2 mg/kg (0.45-0.91 mg/lb).
  • Summary

    DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

No approved side-effect narrative is linked yet.

openFDA reaction signals are available for Dog 52 and Cat 4 (view top reported reactions).

Top Reported Reactions (openFDA)

Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).

Dog
Digestive
Vomiting (427) Diarrhea (179) Blood in vomit (1) Blood in vomit (1) Blood in vomit (1) Blood in vomit (1) Blood in vomit (1) Blood in vomit (1) Loss of appetite (1) Loss of appetite (1) Loss of appetite (1) Loss of appetite (1) Loss of appetite (1) Loss of appetite (1) Vomiting (1) Vomiting (1) Vomiting (1) Vomiting (1) Vomiting (1) Vomiting (1)
Neurologic
Tiredness (lethargy) (249) Head tilt - neurological disorder (1) Head tilt - neurological disorder (1) Head tilt - neurological disorder (1) Head tilt - neurological disorder (1) Head tilt - neurological disorder (1) Neurological disorder NOS (1) Neurological disorder NOS (1) Neurological disorder NOS (1) Neurological disorder NOS (1) Neurological disorder NOS (1) Unsteady walking (ataxia) (1) Unsteady walking (ataxia) (1) Unsteady walking (ataxia) (1) Unsteady walking (ataxia) (1) Unsteady walking (ataxia) (1)
Other
Other abnormal test result NOS (215) Elevated blood urea nitrogen (149) Death by euthanasia (148) Not eating (138) Elevated creatinine (133) Horizontal nystagmus (1) Horizontal nystagmus (1) Horizontal nystagmus (1) Horizontal nystagmus (1) Horizontal nystagmus (1) Musculoskeletal disorder NOS (1) Musculoskeletal disorder NOS (1) Musculoskeletal disorder NOS (1) Musculoskeletal disorder NOS (1) Musculoskeletal disorder NOS (1) Stumbling gait (1)
Cat
Neurologic
Tiredness (lethargy) (1)
Other
Accidental exposure (1) Ecchymosis (1) Labeled drug-species interaction (1)

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Hound - Italian, Male, 13 year, 6.07 kilogram • Drug: MSK, Tablet, Oral • Reactions: Loss of appetite, Stumbling gait • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-052828
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 13.00 Year
  • Weight: 6.070 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
Reactions Reported:
Loss of appetite Stumbling gait
Outcomes: Ongoing

Dog, Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog), Female, 10 year, 16.329 kilogram • Drug: MSK, Tablet, chewable, Oral • Reactions: Blood in vomit, Vomiting • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-050081
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 16.329 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet, chewable
Reactions Reported:
Blood in vomit Vomiting
Outcomes: Ongoing

Dog, Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog), Female, 12 year, 18.597 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Seizure NOS, Neurological disorder NOS, Musculoskeletal disorder NOS, Vestibular disorder NOS, Head tilt - neurological disorder… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-050071
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 12.00 Year
  • Weight: 18.597 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Seizure NOS Neurological disorder NOS Musculoskeletal disorder NOS Vestibular disorder NOS Head tilt - neurological disorder Unsteady walking (ataxia) Horizontal nystagmus
Outcomes: Ongoing

Dog, ['Pit Bull', 'Dog (unknown)'], Female, 11 year, 27.2 kilogram • Drug: MSK, Tablet, Oral, Dose: 0.50 tablet per animal, Frequency: 1 per day • Reactions: Inappetence, Tiredness (lethargy), Loss of appetite, Bloody stool, Decreased haematocrit… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-049833
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 27.200 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 0.50 tablet per animal
  • Frequency: 1 per day
Reactions Reported:
Inappetence Tiredness (lethargy) Loss of appetite Bloody stool Decreased haematocrit Low platelet count Sarcoma NOS Weight loss
Outcomes: Outcome Unknown

Dog, ['Retriever - Labrador', 'Dog (unknown)'], Male, 3 year, 30.844 kilogram • Drug: MSK, Unassigned, Oral • Reactions: General illness, Limping, Arthritis, Pain NOS, Falling… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-047645
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 3.00 Year
  • Weight: 30.844 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
General illness Limping Arthritis Pain NOS Falling Inappropriate urination Inappropriate defecation Seizure NOS Death Elevated creatinine
Outcomes: Died

Cat, Domestic Shorthair, Male, 24 month, 4.128 kilogram • Drug: MSK, Tablet, Oral, Dose: 0.50 tablet per unknown • Reactions: Tiredness (lethargy), Accidental exposure, Labeled drug-species interaction • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2019-US-042456
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 24.00 Month
  • Weight: 4.128 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 0.50 tablet per unknown
Reactions Reported:
Tiredness (lethargy) Accidental exposure Labeled drug-species interaction
Outcomes: Recovered/Normal

Cat, Domestic Mediumhair, Male, 11.5 year, 3.402 kilogram • Drug: MSK, Tablet, Oral, Dose: 7.35 Milligram per kilogram • Reactions: Ecchymosis • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2016-US-043496
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.50 Year
  • Weight: 3.402 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 7.35 Milligram per kilogram
Reactions Reported:
Ecchymosis
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.